



**HAL**  
open science

## Oxygenation management during veno-arterial ECMO support for cardiogenic shock: a multicentric retrospective cohort study

Hadrien Winiszewski, Thibault Vieille, Pierre-Grégoire Guinot, Nicolas Nesseler, Mael Le Berre, Laure Crognier, Anne-Claude Roche, Jean-Luc Fellahi, Nicolas D'ostrevy, Zied Ltaief, et al.

### ► To cite this version:

Hadrien Winiszewski, Thibault Vieille, Pierre-Grégoire Guinot, Nicolas Nesseler, Mael Le Berre, et al.. Oxygenation management during veno-arterial ECMO support for cardiogenic shock: a multicentric retrospective cohort study. *Annals of Intensive Care*, 2024, 14 (1), pp.56. 10.1186/s13613-024-01286-2 . hal-04574993

**HAL Id: hal-04574993**

**<https://hal.science/hal-04574993>**

Submitted on 24 May 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



# Oxygenation management during veno-arterial ECMO support for cardiogenic shock: a multicentric retrospective cohort study

Hadrien Winiszewski<sup>1,17\*</sup> , Thibault Vieille<sup>1</sup>, Pierre-Grégoire Guinot<sup>2</sup>, Nicolas Nessler<sup>3</sup>, Mael Le Berre<sup>1</sup>, Laure Crognier<sup>4</sup>, Anne-Claude Roche<sup>5</sup>, Jean-Luc Fellahi<sup>6</sup>, Nicolas D'Ostrevy<sup>7</sup>, Zied Ltaief<sup>8</sup>, Juliette Didier<sup>9</sup>, Osama Abou Arab<sup>10</sup>, Simon Meslin<sup>11</sup>, Vincent Scherrer<sup>12</sup>, Guillaume Besch<sup>13</sup>, Alexandra Monnier<sup>14</sup>, Gael Piton<sup>1</sup>, Antoine Kimmoun<sup>15</sup> and Gilles Capellier<sup>1,16</sup>

## Abstract

**Background** Hyperoxemia is common and associated with poor outcome during veno-arterial extracorporeal membrane oxygenation (VA ECMO) support for cardiogenic shock. However, little is known about practical daily management of oxygenation. Then, we aim to describe sweep gas oxygen fraction ( $F_{S}O_2$ ), postoxygenator oxygen partial pressure ( $P_{POST}O_2$ ), inspired oxygen fraction ( $F_I O_2$ ), and right radial arterial oxygen partial pressure ( $P_a O_2$ ) between day 1 and day 7 of peripheral VA ECMO support. We also aim to evaluate the association between oxygenation parameters and outcome. In this retrospective multicentric study, each participating center had to report data on the last 10 eligible patients for whom the ICU stay was terminated. Patients with extracorporeal cardiopulmonary resuscitation were excluded. Primary endpoint was individual mean  $F_{S}O_2$  during the seven first days of ECMO support ( $F_{S}O_2$  mean (day 1–7)).

**Results** Between August 2019 and March 2022, 139 patients were enrolled in 14 ECMO centers in France, and one in Switzerland. Among them, the median value for  $F_{S}O_2$  mean (day 1–7) was 70 [57; 79] % but varied according to center case volume. Compared to high volume centers, centers with less than 30 VA-ECMO runs per year were more likely to maintain  $F_{S}O_2 \geq 70\%$  (OR 5.04, CI 95% [1.39; 20.4],  $p=0.017$ ). Median value for right radial  $P_a O_2$  mean (day 1–7) was 114 [92; 145] mmHg, and decreased from 125 [86; 207] mmHg at day 1, to 97 [81; 133] mmHg at day 3 ( $p < 0.01$ ). Severe hyperoxemia (i.e. right radial  $P_a O_2 \geq 300$  mmHg) occurred in 16 patients (12%).  $P_{POST}O_2$ , a surrogate of the lower body oxygenation, was measured in only 39 patients (28%) among four centers. The median value of  $P_{POST}O_2$  mean (day 1–7) value was 198 [169; 231] mmHg. By multivariate analysis, age (OR 1.07, CI95% [1.03–1.11],  $p < 0.001$ ),  $F_{S}O_2$  mean (day 1–3) (OR 1.03 [1.00–1.06],  $p=0.039$ ), and right radial  $P_a O_2$  mean (day 1–3) (OR 1.03, CI95% [1.00–1.02],  $p=0.023$ ) were associated with in-ICU mortality.

\*Correspondence:  
Hadrien Winiszewski  
hwiniszewski@chu-besancon.fr

Full list of author information is available at the end of the article

**Conclusion** In a multicentric cohort of cardiogenic shock supported by VA ECMO, the median value for  $F_S O_2$   $mean (day 1-7)$  was 70 [57; 79] %.  $P_{POST} O_2$  monitoring was infrequent and revealed significant hyperoxemia. Higher  $F_S O_2$   $mean (day 1-3)$  and right radial  $P_a O_2$   $mean (day 1-3)$  were independently associated with in-ICU mortality.

**Keywords** Extracorporeal membrane oxygenation, Cardiogenic shock, Hyperoxia, Sweep gas oxygen fraction, Mortality

## Background

While Venous-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) is primarily used to restore adequate tissue perfusion by increasing systemic blood flow, it also significantly impacts blood oxygenation because of the oxygenator integrated into the circuit. Indeed, severe hyperoxemia (i.e.  $P_a O_2 \geq 300$  mmHg) is commonly reported during VA-ECMO support, with prevalence ranging from 12 to 89% during the first 24 h [1–9]. Several studies have reported an association between severe hyperoxemia and poor outcome in this population, especially after refractory cardiac arrest [2–7, 9–11]. In the setting of cardiogenic shock rescued by VA-ECMO, although initial studies did not find such association [1, 7], there is emerging data supporting the link between hyperoxemia and mortality [8, 12, 13].

Based on these observational studies, the 2021 ELSO guidelines have recommended to target slight hyperoxemia after the oxygenator ( $P_{POST} O_2$  around 150 mmHg) and to avoid hypoxemia on the right radial artery [14]. Such guidelines open to wide variation in clinical practice, as it is still unknown how to reach these oxygenation's targets. Indeed, because of the dual circulation, right radial  $P_a O_2$  is impacted by both the ventilator settings (inspired fraction of oxygen ( $F_I O_2$ ) and positive end expiratory pressure (PEEP)), the ECMO blood flow, and the sweep gas oxygen fraction ( $F_S O_2$ ) [15, 16].

To date, there is very limited data on oxygenation management during VA-ECMO support for cardiogenic shock, all studies reporting monocentric or bicentric experiences, and limited to the first 24 h [7, 8], 48 h [12], or 72 h [1]. Then, we aimed to describe the current oxygenation management for the first week of VA ECMO support in a multicentric cohort of patients with cardiogenic shock. We also aimed to evaluate the association between oxygenation parameters and outcome.

## Methods

This was a retrospective cohort multicentric study conducted in 14 intensive care units (ICU) in France, and one ICU in Switzerland. The study was approved by our institutional review board in August 2021 (“ECMOxy: oxygenation practice in patients with cardiogenic shock supported by VA ECMO”, approval number EI/2021/1061). This was considered as a multicentric Evaluation of Professional Practices. Aiming at improving quality of care, this French legal framework allows

collection of anonymized data related to standard care without need of written patient's consent. However, in Switzerland, the consent of the patient or his surrogate was mandatory. The research was performed in accordance with the ethical standards in the 1964 Declaration of Helsinki and its later amendments.

## Patients

Inclusion criteria were adult patients, supported by VA-ECMO for refractory cardiogenic shock, and having available data on  $F_S O_2$  from the day of implantation (day 1) to day 7 (or the day of weaning if before day 7). Exclusion criteria were extracorporeal cardiopulmonary resuscitation (ECPR), and ECMO duration less than 24 h. Each participating center had to report data on the last 10 eligible patients for whom the ICU stay was terminated.

## Data collection

The following data were collected: demographic data, characteristic of centers, indication for VA-ECMO support, VA-ECMO configuration, Simplified Acute Physiology Score 2 (SAPS2) and Sequential Organ Failure Assessment (SOFA) score, data related to extracorporeal oxygenation ( $F_S O_2$  two times daily, and postoxygenator oxygen partial pressure ( $P_{POST} O_2$ ) if available), data related to systemic oxygenation ( $F_I O_2$ , oxygen partial pressure on the right radial artery ( $P_a O_2$ ), tidal volume, PEEP, and extubation), and data related to clinical outcome (need for renal replacement therapy, ECMO duration, ECMO weaning, LVAD implantation, heart transplantation, and in-ICU mortality, i.e. death during the same ICU stay than ECMO cannulation). Oxygenation related data were reported from day 1 to day 7 of VA-ECMO support (or the day of weaning if before day 7).

## Endpoints

Primary endpoint was individual mean  $F_S O_2$  during the seven first days of ECMO support ( $F_S O_2$   $mean (day 1-7)$ ). Secondary endpoints were individual mean  $F_S O_2$  during the three first days ( $F_S O_2$   $mean (day 1-3)$ ), individual mean right radial  $P_a O_2$  during the seven first days (right radial  $P_a O_2$   $mean (day 1-7)$ ), prevalence of  $P_{POST} O_2$  monitoring, prevalence of extubation, and factors associated with in-ICU mortality.

### Statistical analysis

According to a Shapiro test, the studied variables were not normally distributed. Quantitative parameters were then described as median [Interquartile range] and number (percentage).  $F_5O_2$  was dichotomized at the median value in the overall population (70%).

First, univariate analysis was performed to identify factors significantly associated with  $F_5O_2 \text{ mean (day 1-7)} \geq 70\%$  and with in-ICU mortality. Wilcoxon test was used to compare quantitative parameters and Chi-square test or Fisher exact test for qualitative parameters. A Wilcoxon signed rank test was used to compare repeated variables.

Second, we performed a multivariate logistic regression analysis to identify factors independently associated with  $F_5O_2 \text{ mean (day 1-7)} \geq 70\%$ . Variables associated with  $F_5O_2 \text{ mean (day 1-7)} \geq 70\%$  with a  $p$  value of less than 0.1 by univariate analysis were introduced in the model.

Third, we performed a multivariate logistic regression analysis to identify factors associated with in-ICU mortality. We entered factors associated with in-ICU mortality identified by univariate analysis as well as the duration of ECMO given its potential relevance. We then proceeded to a stepwise AIC backward regression. Multicollinearity between variables of the model was assessed using variance inflation factors. We evaluated

the goodness of fit of logistic regression models with a Hosmer Lemeshow test. In case of missing data, no imputation was carried out because they were below 5%. A  $p$  value of less than 0.05 was considered statistically significant. Statistical analysis was performed with R version 4.0.3.

## Results

### Patients and centers

The first patient received VA ECMO in August 2019 and the last in March 2022. Although it was asked to report data for 10 patients, three centers reported data for 5 (5 consent withdrawals in a center in Switzerland), 9 (1 duplicate), and 11 patients, respectively. Data were available for 145 patients. Because oxygenation physiology is very different in peripheral and central ECMO, we secondarily decided to exclude the 6 patients with central ECMO, and 139 patients were finally analyzed.

Acute coronary syndrome was the main cause of cardiogenic shock ( $n=50$ , 36%), followed by acutely decompensated cardiomyopathy ( $n=44$ , 32%), and post-cardiotomy shock ( $n=26$ , 19%). ECMO was mainly inserted through femoral vessels ( $n=129$ , 93%). ECMO was successfully weaned in 100 patients (72%), and 87 patients were discharged alive from ICU (63%). Baseline patient's characteristics are reported in Table 1. Among the 15 participating centers, 4 used to manage less than 30 VA-ECMO patients/year, 9 between 30 and 100 VA ECMO patients/year, and 2 used to manage more than 100 VA ECMO patients/year.

### Oxygenation management

#### $F_5O_2$

Among the 139 patients, the median value for  $F_5O_2 \text{ mean (day 1-7)}$  was 70 [57; 79] % and  $F_5O_2$  did not differ between day 1 and day 3 (Wilcoxon signed rank test,  $p=0.37$ ). However,  $F_5O_2 \text{ mean (day 1-7)}$  varied between centers, ranging from 46 [43; 58] % to 84 [80; 92] %. Regarding to center case-volume,  $F_5O_2 \text{ mean (day 1-7)}$  was 72 [70; 81] %, 69 [57; 78] %, and 55 [44; 69] % in centers managing <30, between 30 and 100, and >100 VA ECMO per year, respectively ( $p<0.01$ ).  $F_5O_2 \text{ mean (day 1-7)}$  was 66 [50; 76] % in patients extubated during ECMO support, and 70 [59; 80] % in non-extubated patients ( $p=0.04$ ). In the whole cohort, 24 patients (17%) experienced at least one day with a  $F_5O_2$  set at 100%. Descriptive data on oxygenation parameters are summarized in Table 2.

By univariate analysis, center case-volume ( $p=0.01$ ), and right radial  $P_aO_2 \text{ mean (day 1-7)}$  ( $p<0.01$ ) were associated with  $F_5O_2 \text{ mean (day 1-7)} \geq 70\%$ . By multivariate analysis, centers with case-volume <30 per year (OR 5.04, CI 95% [1.39; 20.4],  $p=0.017$ ), and right radial  $P_aO_2 \text{ mean (day 1-7)}$  (OR 1.01, CI 95% [1.00; 1.02],  $p=0.006$ ) were

**Table 1** Baseline characteristics

Patients characteristics	Patients (n = 139)
Age (years)	57 [47;62]
SAPS2 score	60 [47;77]
SOFA score	10 [7;13]
Number of patients according to centers case-volume per year	
<30	32 (23%)
30-100	88 (63%)
>100	19 (14%)
Indication for VA ECMO	
Acute coronary syndrome	50 (36%)
Cardiomyopathy	44 (32%)
Postcardiotomy	26 (19%)
Pulmonary embolism	7 (5%)
Drug poisoning	7 (5%)
Others	5 (3%)
ECMO configuration	
Femoro-femoral	129 (93%)
Femoro-axillar	10 (7)
Outcome	
RRT during ICU stay	55 (40%)
ECMO duration (days)	6 [4-8]
ECMO weaning	100 (72%)
Bridge to LVAD	10 (7%)
Bridge to transplant	16 (12%)
ICU survival	87 (63%)

Data are number (percentage) and median [Interquartile range]. SAPS2: Simplified acute physiology score; SOFA: sequential organ failure assessment; LVAD: left ventricle assist device; RRT: renal replacement therapy

**Table 2** Description of oxygenation parameters among the 139 patients supported by peripheral VA ECMO

Oxygenation parameters	F <sub>S</sub> O <sub>2</sub> (%)		F <sub>I</sub> O <sub>2</sub> (%)		Right radial P <sub>a</sub> O <sub>2</sub> (mmHg)
<i>Mean value</i>					
From day 1 to day 7	70 [57;79]		44 [35;57]		114 [92;145]
From day 1 to day 3	70 [60;80]		45 [35;60]		117 [90;158]
<i>Daily evolution</i>					
Day 1 (n = 139)	70 [60;80]*		50 [37;70]**		125 [86;207]***
Day 2 (n = 136)	70 [60;80]		40 [30;60]		106 [78;139]
Day 3 (n = 132)	70 [57;80]*		40 [30;60]**		97 [81;133]***
Day 4 (n = 117)	70 [60;80]		40 [30;60]		94 [79;116]
Day 5 (n = 97)	70 [60;80]		40 [33;53]		96 [79;129]
Day 6 (n = 78)	70 [60;80]		40 [30;50]		88 [78;114]
Day 7 (n = 68)	70 [59;80]		40 [30;50]		95 [80;136]
<i>Center case volume (per year)</i>					
< 30	F <sub>S</sub> O <sub>2 mean (day 1-7)</sub> 72 [70;81]	p < 0.01	F <sub>I</sub> O <sub>2 mean (day 1-7)</sub> 46 [38;57]	p = 0.18	Right radial P <sub>a</sub> O <sub>2 mean (day 1-7)</sub> 115 [92;155] p = 0.04
30-100	69 [57;78]		47 [35;59]		116 [96;147]
> 100	55 [44;69]		36 [30;46]		98 [87;112]
<i>Extubation during ECMO support</i>					
Yes	F <sub>S</sub> O <sub>2 mean (day 1-7)</sub> 66 [50;76]	p = 0.04	F <sub>I</sub> O <sub>2 mean (day 1-7)</sub> 34 [29;39]	p < 0.01	Right radial P <sub>a</sub> O <sub>2 mean (day 1-7)</sub> 102 [87;122] p = 0.01
No	70 [59;80]		51 [42;64]		118 [97;151]

Data are median [Interquartile range]; F<sub>S</sub>O<sub>2</sub>: sweep gas oxygen fraction; F<sub>I</sub>O<sub>2</sub>: inspired oxygen fraction; p: p value

\*Comparison between F<sub>S</sub>O<sub>2 day 1</sub> and F<sub>S</sub>O<sub>2 day 3</sub>: p = 0.37

\*\* Comparison between F<sub>I</sub>O<sub>2 day 1</sub> and F<sub>I</sub>O<sub>2 day 3</sub>: p < 0.01

\*\*\* Comparison between right radial P<sub>a</sub>O<sub>2 day 1</sub> and right radial P<sub>a</sub>O<sub>2 day 3</sub>: p < 0.01

associated with F<sub>S</sub>O<sub>2 mean (day 1-7)</sub> ≥ 70% (Supplementary Table 1).

### F<sub>I</sub>O<sub>2</sub>

The median value of F<sub>I</sub>O<sub>2 mean (day 1-7)</sub> was 44 [35; 57] %. There was no statistically difference in F<sub>I</sub>O<sub>2</sub> according to center case volume (p = 0.18). Median value of F<sub>I</sub>O<sub>2 mean (day 1-7)</sub> was 34 [29; 39] % in patients extubated at least one day during ECMO support, and 51 [42; 64] % in non-extubated patients (p < 0.01) (Table 2).

### Right radial P<sub>a</sub>O<sub>2</sub>

Among the 139 patients, 723 right radial P<sub>a</sub>O<sub>2</sub> values were available during the seven first days of ECMO support. Data were missing for 7 patients, in whom P<sub>a</sub>O<sub>2</sub> was monitored at the left radial artery.

Median value of right radial P<sub>a</sub>O<sub>2 mean (day 1-7)</sub> was 114 [92; 145] mmHg. Right radial P<sub>a</sub>O<sub>2</sub> decreased from 125 [86;207] mmHg at day 1, to 97 [81;133] mmHg at day 3 (Wilcoxon signed rank test p < 0.01). Regarding to center case volume right radial P<sub>a</sub>O<sub>2 mean (day 1-7)</sub> was 115 [92;155], 116 [96;147] and 98 [87;112] mmHg in centers managing < 30, between 30 and 100, and > 100 VA ECMO per year, respectively (p = 0.04). Right radial P<sub>a</sub>O<sub>2 mean (day 1-7)</sub> was 102 [87; 122] mmHg in patients extubated during ECMO support, and 118 [97; 151] mmHg in non-extubated patients (p = 0.01) (Table 2).

Among the 723 available right radial P<sub>a</sub>O<sub>2</sub> values, 77 (11%) and 22 (3%) were ≥ 200 mmHg and ≥ 300 mmHg, respectively. Among the 139 patients, 16 (12%) experienced severe hyperoxemia, defined as at least one episode


of right radial P<sub>a</sub>O<sub>2</sub> ≥ 300 mmHg. Daily evolution of right radial P<sub>a</sub>O<sub>2</sub> ranges distribution is reported in Fig. 1. Evolution of right radial P<sub>a</sub>O<sub>2</sub> according to center case volume and outcome is presented in Supplementary Fig. 2.

### Tidal volume, PEEP, and extubation

On the day of ECMO implantation, 115 patients (83%) were intubated. Among them, median tidal volume and PEEP during the study period were 6.2 [5.7; 6.9] mL/kg of predicted body weight, and 7 [6; 9] cmH<sub>2</sub>O, respectively. During the seven first days of ECMO support, 47 patients (34%) were extubated at least one day. The median delay between ECMO start and extubation was 1 [0; 2] days.

### P<sub>POST</sub>O<sub>2</sub>

Among the 15 participating ICUs, 8 (53%) did not use to monitor daily P<sub>POST</sub>O<sub>2</sub> and had no available data. In the remaining seven, 3 used to measure P<sub>POST</sub>O<sub>2</sub> once daily but with F<sub>S</sub>O<sub>2</sub> transiently increased at 100%. This aims at testing the membrane gas transfer capacity, rather than detecting ECMO-induced hyperoxemia of the lower part of the body. In the remaining four centers measuring P<sub>POST</sub>O<sub>2</sub> maintaining F<sub>S</sub>O<sub>2</sub> at its actual value, 39 patients (28%) had available data, and median value of P<sub>POST</sub>O<sub>2 mean (day 1-7)</sub> value was 198 [169; 231] mmHg. Evolution of P<sub>POST</sub>O<sub>2</sub> between day 1 and 7 is reported in Supplementary Fig. 1. Out of the 215 available P<sub>POST</sub>O<sub>2</sub> values, 142 (66%) were above 150 mmHg. Among the 139 patients of the cohort, 44 (32%) had at least one day with F<sub>S</sub>O<sub>2</sub> ≤ 50% without P<sub>POST</sub>O<sub>2</sub> monitoring.



**Fig. 1** Right radial  $P_aO_2$  ranges distribution

### Association of oxygenation parameters and in-ICU mortality

By univariate analysis, age ( $p < 0.01$ ), SAPS2 score ( $p < 0.01$ ),  $F_{S_2O_2}$  day 2 ( $p = 0.02$ ),  $F_{S_2O_2}$  day 3 ( $p < 0.01$ ),  $F_{S_2O_2}$  mean (day 1–3) ( $p < 0.01$ ),  $F_{S_2O_2} > 70\%$  day 2 (i.e. at least one  $F_{S_2O_2}$  value  $> 70\%$  on day 2) ( $p = 0.03$ ),  $F_{S_2O_2} > 70\%$  day 3 ( $p = 0.02$ ),  $F_{S_2O_2} > 70\%$  day 1–3 ( $p = 0.04$ ) and right radial  $P_aO_2$  mean (day 1–3) ( $p = 0.01$ ) were associated with in-ICU mortality. We entered 5 variables in the multivariate logistic regression analysis: age, SAPS2,  $F_{S_2O_2}$  mean (day 1–3), and right radial  $P_aO_2$  mean (day 1–3); the duration of ECMO was also introduced in the model given its clinical relevance. Using a stepwise AIC backward regression analysis, three out of these five variables were conserved in the final model: age (OR 1.07, CI95% [1.03–1.11],  $p < 0.001$ ),  $F_{S_2O_2}$  mean (day 1–3) (OR 1.03 [1.00–1.06],  $p = 0.039$ ), and right radial  $P_aO_2$  mean (day 1–3) (OR 1.03, CI95% [1.00–1.02],  $p = 0.023$ ). On the contrary, ECMO duration and SAPS2 score were not independently associated with in-ICU mortality, and were therefore removed during the stepwise logistic regression analysis.

Univariate and multivariate analysis of factor associated with in-ICU mortality is reported in Table 3. Day by day comparison of  $F_{S_2O_2}$  according to outcome is presented in Fig. 2.

### Discussion

In this multicentric cohort study of cardiogenic shock supported by VA ECMO, results may be summarized as follow: (1) median value of  $F_{S_2O_2}$  mean (day 1–7) was 70 [57; 79] %; (2)  $P_{POST}O_2$  (a surrogate of lower body  $PO_2$ ) monitoring was infrequent and revealed significant hyperoxemia, and (3) higher  $F_{S_2O_2}$  mean (day 1–3) and right radial  $P_aO_2$  mean (day 1–3) were independently associated with in-ICU mortality.

Published data on  $F_{S_2O_2}$  management are scarce. Most of studies report either only punctual  $F_{S_2O_2}$  values [17, 18], or protocol for the initial  $F_{S_2O_2}$  setting [1, 2, 5, 6, 19]. In a retrospective monocentric study on 54 patients, median  $F_{S_2O_2}$  decreased from 80% [70–100] at baseline, to 70% [65–80] at 48 h [20]. In another study, mean  $F_{S_2O_2}$  was around 80% between day 1 and day 10 of ECMO support [21]. In the study by Moussa et al., mean  $F_{S_2O_2}$  ranged from 50% to 70% between baseline and day 2 [12]. Our data are in line with the previous studies, showing that  $F_{S_2O_2}$  is usually set around 70%. Interestingly, we found that  $F_{S_2O_2}$  varied inversely with ECMO center case volume. Because right radial  $P_aO_2$  was also higher in low volume centers, we can hypothesize that low volume centers were more tolerant with hyperoxemia, leading to less down titration of  $F_{S_2O_2}$  compared to most experienced centers. However, such observation needs to be interpreted cautiously because only 23% and 14% of patients were enrolled in low and high-volume centers. Then, this difference may reflect practices of a very few centers rather than a real case volume effect.

Using the threshold of 300 mmHg for the right radial  $P_aO_2$ , we found a quite low prevalence of severe hyperoxemia (12%). Our results are concordant with those of Jentzer et al. who found a 19.8% prevalence of severe hyperoxemia 24 h after ECMO start for cardiogenic shock [8]. This observation should probably be linked to an early  $F_{S_2O_2}$  titration, as only 17% of patients of our cohort experienced at least one day with a  $F_{S_2O_2}$  set at 100%.

Although  $P_{POST}O_2$  was a main objective of the study, we found that  $P_{POST}O_2$  monitoring was infrequent. It is important to distinguish  $P_{POST}O_2$  monitoring, i.e.  $PO_2$  monitoring of the blood reinjected in the abdominal aorta which can be assimilated to the hepato-splanchnic

**Table 3** Univariate and multivariate analyses of factors associated with in-ICU mortality among the 139 patients supported by peripheral VA ECMO

Patients characteristics	Univariate analysis			Multivariate analysis	
	Survivors (n=87)	Non-survivors (n=52)	p value	OR [CI 95%]	p value
Age (years)	52 [45;59]	62 [57;67]	< 0.01	1.07 [1.03–1.11]	< 0.001
SAPS2 score	56 [45;67]	72 [48;81]	< 0.01	-	-
SOFA score	10 [7;12]	11 [8;13]	0.23	-	-
<i>Center case-volume (VA ECMO/year)</i>					
< 30	20/87	12/52	0.28	-	-
30–100	52/87	36/52		-	-
> 100	15/87	4/52		-	-
ECMO duration (days)	6 [4;9]	7 [4;8]	0.6	-	-
F <sub>S</sub> O <sub>2</sub> day 1 (%)	65 [60;80]	70 [60;90]	0.11	-	-
F <sub>S</sub> O <sub>2</sub> day 2 (%)	65 [50;78]	70 [60;80]	0.02	-	-
F <sub>S</sub> O <sub>2</sub> day 3 (%)	70 [51;75]	75 [65;84]	< 0.01	-	-
F <sub>S</sub> O <sub>2</sub> mean (day 1–3) (%)	67 [54;75]	72 [65;85]	< 0.01	1.03 [1.00–1.06]	0.039
F <sub>S</sub> O <sub>2</sub> day 1 > 70%*	51/87	34/52	0.48	-	-
F <sub>S</sub> O <sub>2</sub> day 2 > 70%*	49/87	37/49	0.03	-	-
F <sub>S</sub> O <sub>2</sub> day 3 > 70%*	47/86	35/46	0.02	-	-
F <sub>S</sub> O <sub>2</sub> day 1–3 > 70%*	39/87	33/52	0.04	-	-
Right radial P <sub>a</sub> O <sub>2</sub> day 1 (mmHg)	120 [88;183]	165 [82;242]	0.21	-	-
Right radial P <sub>a</sub> O <sub>2</sub> day 2 (mmHg)	99 [77;128]	114 [86;156]	0.06	-	-
Right radial P <sub>a</sub> O <sub>2</sub> day 3 (mmHg)	94 [81;120]	109 [82;162]	0.08	-	-
Right radial P <sub>a</sub> O <sub>2</sub> mean (day 1–3) (mmHg)	111 [90;146]	141 [100;197]	0.01	1.03 [1.00–1.02]	0.023

Data are number and median [Interquartile range] OR: Odds ratio; CI95%: confidence interval; SAPS2: simplified acute; F<sub>S</sub>O<sub>2</sub>: Sweep gas oxygen fraction

\* F<sub>S</sub>O<sub>2</sub> day X > 70% corresponds to at least one F<sub>S</sub>O<sub>2</sub> value > 70% on day X


Bold values are p values < 0.05

PO<sub>2</sub> monitoring, and functional membrane assessment evaluated once daily by increasing F<sub>S</sub>O<sub>2</sub> transiently at 100% to determine the gas transfer capacity of the membrane. Some clinicians may consider P<sub>POST</sub>O<sub>2</sub> monitoring useless, as right radial P<sub>a</sub>O<sub>2</sub> may be sufficient to detect ECMO-induced hyperoxemia, and differential hypoxemia. In the subgroup of patients with available data, we found significant hyperoxemia with a median P<sub>POST</sub>O<sub>2</sub> value of 198 mmHg, and two third of values above the ELSO recommended target of 150 mmHg [14]. Previously, only one study on 45 patients has reported data regarding to P<sub>POST</sub>O<sub>2</sub>. They found that median P<sub>POST</sub>O<sub>2</sub> decreased from 301 [215–386] mmHg at baseline, to 140

[78–220] mmHg at H48. In this study, only one third of P<sub>POST</sub>O<sub>2</sub> values were below 150 mmHg [20]. A possible reason for this tolerance with hyperoxemia might be the fear of unrecognized hypoxemia of the lower part of the body. Indeed, devices for continuous monitoring of P<sub>POST</sub>O<sub>2</sub> or postoxygenerator oxygen saturation exist but are not widespread. Then down titration of F<sub>S</sub>O<sub>2</sub> might theoretically result in unknown low P<sub>POST</sub>O<sub>2</sub>, and hepato-splanchnic hypoxia [15]. One could also argue that for now, the safe P<sub>POST</sub>O<sub>2</sub> target is still unknown, as randomized trials are ongoing [22].

Although in the setting of ECPR, most of studies have reported an association between P<sub>a</sub>O<sub>2</sub> and outcome [2, 4–7, 9–11, 23], results are not so clear for patients with cardiogenic shock supported by VA-ECMO. Based on the ELSO registry, Munshi et al. did not found any association between P<sub>a</sub>O<sub>2</sub> 24 h after ECMO start and mortality in the subgroup of 775 patients with cardiogenic shock [7]. In a smaller cohort by Ross et al., mean P<sub>a</sub>O<sub>2</sub> of the 72 first hours was also not associated with mortality [1]. However, more recently, Moussa et al. reported that early hyperoxemia was associated with mortality in a cohort of 430 patients. In this study, mean P<sub>a</sub>O<sub>2</sub>, absolute peak P<sub>a</sub>O<sub>2</sub>, and mean daily peak P<sub>a</sub>O<sub>2</sub> during the 48 first hours were associated with 28-day mortality [12]. An analysis of 9959 patients in the ELSO registry found an association between hyperoxemia (P<sub>a</sub>O<sub>2</sub> > 150 mmHg 24 h after ECMO start) and in-hospital mortality [8]. Our results are in line with these findings.

Beyond the already described link between P<sub>a</sub>O<sub>2</sub> and outcome, we found that F<sub>S</sub>O<sub>2</sub> mean (day 1–3) was independently associated with in-ICU mortality. Such finding is of interest because it may help to distinguish if hyperoxemia is a culprit or only a covariate [22]. Indeed, such link between hyperoxemia and prognosis might either be mediated by the proper harm of ECMO-associated hyperoxemia or be biased by the severity of cardiac failure. In the setting of peripheral VA-ECMO, the differential hypoxemia phenomenon results in heterogeneous PO<sub>2</sub> along the aorta, depending of the location of the mixing zone [24]. In the most severe cardiac failure, the mixing zone is in the aortic arch, close to the brachio-cephalic trunk. Then, right radial P<sub>a</sub>O<sub>2</sub> is mainly determined by F<sub>S</sub>O<sub>2</sub> and its value is closed to the P<sub>POST</sub>O<sub>2</sub> value. In the absence of measurement of stroke volume or its surrogates (pulse pressure or end tidal CO<sub>2</sub> [25]), we cannot rule out that patients with higher right radial P<sub>a</sub>O<sub>2</sub> were those with the most severe cardiac failure, having per se a higher mortality [26]. The fact that a higher F<sub>S</sub>O<sub>2</sub> mean (day 1–3) was independently associated with a higher in-ICU mortality supports the hypothesis of the proper harm of ECMO-induced hyperoxemia, as F<sub>S</sub>O<sub>2</sub> may not be impacted by cardiac failure severity. Indeed, higher F<sub>S</sub>O<sub>2</sub> mean (day 1–3) may have resulted in



**Fig. 2** Day by day comparison of  $F_5O_2$  according to outcome.  $F_5O_2$ : Sweep gas oxygen fraction

higher  $P_{POST}O_2$ , and potentially more reperfusion injury of the gut [27], liver, and kidneys. Interestingly, in the study of Moussa et al., the mean  $F_5O_2$  was lower in survivors than in non-survivors [12]. In the study of Justus et al., the median  $F_5O_2$  also tended to be lower in survivors than in non-survivors (72% versus 78%) [21].

Our study has strengths. First, the multicentric design allowed us to detect a signal of variability of oxygenation practices according to center's case volume. Second, we collected data during seven days after ECMO implantation, which corresponds to almost the whole duration of VA-ECMO support. We think that it is more adapted to study the real impact of ECMO-induced hyperoxemia than focusing on the first 24 h of support.

Our study has also several limitations. First, while we hypothesized that the association between  $F_5O_2$  mean (day 1–3) and in-ICU mortality was mediated by the  $P_{POST}O_2$  value, we were unable to confirm it because  $P_{POST}O_2$  monitoring was infrequent, even in high-volume centers. We also did not collect data on ECMO blood flow, which has been recently demonstrated to be a major determinant of right radial  $P_aO_2$  [20]. Because the primary objective of the study was description of oxygenation practices, we also did not collect data allowing to evaluate the impact of ECMO-induced hyperoxemia on organ dysfunction. Second, our study was mostly conducted in France. Epidemiological data from another country may have led to different observation. Third, we did not find any association between centers case volume and in-ICU mortality. It is however commonly admitted that center's case volume is associated with improved outcome [28]. These results might be explained by the limited sample size, the fact that most of patients were admitted in medium volume centers, and the short-term outcome (in-ICU mortality). Finally, due to the inclusion criteria

(last 10 patients with cardiogenic shock supported VA ECMO for more than 24 h), data may reflect oxygenation practices over up to two years in low volume centers, compared to only 3 months in high volume centers.

## Conclusion

In a multicentric cohort study of cardiogenic shock supported by VA ECMO, median value of  $F_5O_2$  mean (day 1–7) was 70 [57; 79] %.  $P_{POST}O_2$  monitoring was infrequent but revealed significant hyperoxemia. Higher  $F_5O_2$  mean (day 1–3) and right radial  $P_aO_2$  mean (day 1–3) were independently associated with in-ICU mortality. Based on these results, we can hypothesize that a strategy of systematic daily monitoring of  $P_{POST}O_2$  may help to down titrate  $F_5O_2$  and reduce ECMO-associated hyperoxemia and its potential deleterious effects.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13613-024-01286-2>.

Supplementary Material 1

## Acknowledgements

Not applicable.

## Author contributions

HW and GC designed the study and wrote the manuscript; TV and GP performed statistic and reviewed the manuscript; PGG, MLB, NN, TS, ACR, JLF, AM, ZL, JD, OAA, SM, VS, GB, AM, AK collected data. All authors read and approved the final manuscript.

## Funding

Not applicable.

## Data availability

The datasets used during the current study are available from the corresponding author on reasonable request.



## Declarations

### Ethics approval and consent to participate

The study was approved by our institutional review board in August 2021 ("ECMOxy: oxygenation practice in patients with cardiogenic shock supported by VA ECMO", approval number EI/2021/1061). This was considered as a multicentric Evaluation of Professional Practices. Aiming at improving quality of care, this French legal framework allows collection of anonymized data related to standard care without need of written patient's consent. However, in Switzerland, the consent of the patient or his surrogate was mandatory. The research was performed in accordance with the ethical standards in the 1964 Declaration of Helsinki and its later amendments.

### Consent for publication

Because all data are anonymized, consent for publication is not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Service de réanimation médicale, CHU Besançon, Besançon, France

<sup>2</sup>Service d'anesthésie-réanimation chirurgicale, CHU Dijon, Dijon, France

<sup>3</sup>Department of Anesthesia and Critical Care, University Hospital of Rennes, Pontchaillou, Rennes, France

<sup>4</sup>Intensive Care Unit, Anesthesia and Critical Care Department, Rangueil University Hospital, Toulouse, France

<sup>5</sup>Anesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France

<sup>6</sup>Service d'Anesthésie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France

<sup>7</sup>Cardiac Surgery Department, Montpied Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France

<sup>8</sup>Department of Adult Intensive Care Medicine, Lausanne University Hospital and Lausanne University, Lausanne 1011, Switzerland

<sup>9</sup>Service de médecine intensive réanimation, CHU Pitié Salpêtrière, Paris, France

<sup>10</sup>Department of Anaesthesia and Critical Care Medicine, Amiens University Medical Center, Amiens, France

<sup>11</sup>Anesthesiology and Critical Care Medicine Department, Hôpital Européen Georges Pompidou, APHP, Paris, France

<sup>12</sup>Department of Anaesthesiology and Critical Care, CHU Rouen, Rouen F-76000, France

<sup>13</sup>Département d'Anesthésie Réanimation Chirurgicale, Université de Franche-Comté, CHU Besançon, CIC Inserm 1431, Besançon EA3920, F-25000, France

<sup>14</sup>Service de Médecine Intensive-Réanimation Médicale, CHU Strasbourg, Nouvel Hôpital Civil, Université de Strasbourg, Strasbourg 67000, France

<sup>15</sup>Service de médecine intensive réanimation, CHU Nancy, Crêteil, France

<sup>16</sup>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Clayton, Australia

<sup>17</sup>Research Unit EA 3920 and SFR FED 4234, University of Franche Comté, Besançon, France

Received: 13 December 2023 / Accepted: 2 April 2024

Published online: 10 April 2024

## References

- Ross P, Miller C, Sheldrake J, McGuinness W, Udy A, Burrell A. Hyperoxia in patients with cardiogenic shock after myocardial infarction supported with venoarterial extracorporeal membrane oxygenation. *Aust Crit Care Off J Confed Aust Crit Care Nurses* 2020.
- Chang W-T, Wang C-H, Lai C-H, et al. Optimal arterial blood oxygen tension in the early postresuscitation phase of extracorporeal cardiopulmonary resuscitation: a 15-Year retrospective observational study. *Crit Care Med*; 2019.
- Al-Kawaz MN, Canner J, Caturegli G et al. Duration of Hyperoxia and neurologic outcomes in patients undergoing extracorporeal membrane oxygenation. *Crit Care Med* 2021.
- Bonnemain J, Rusca M, Ltaief Z, et al. Hyperoxia during extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest is associated with severe circulatory failure and increased mortality. *BMC Cardiovasc Disord*. 2021;21(1):542.
- Stoll SE, Paul E, Pilcher D, Udy A, Burrell A. Hyperoxia and mortality in conventional versus extracorporeal cardiopulmonary resuscitation. *J Crit Care*. 2022;69:154001.
- Halter M, Jouffroy R, Saade A, Philippe P, Carli P, Vivien B. Association between hyperoxemia and mortality in patients treated by eCPR after out-of-hospital cardiac arrest. *Am J Emerg Med* 2019.
- Munshi L, Kiss A, Cypel M, Keshavjee S, Ferguson ND, Fan E. Oxygen thresholds and mortality during extracorporeal life support in adult patients. *Crit Care Med* 2017.
- Jentzer JC, Miller PE, Alviar C, Yalamuri S, Bohman JK, Tonna JE. Exposure to arterial hyperoxia during extracorporeal membrane oxygenator support and mortality in patients with cardiogenic shock. *Circ Heart Fail*. 2023;16(4):e010328.
- Shou BL, Ong CS, Premraj L, et al. Arterial oxygen and carbon dioxide tension and acute brain injury in extracorporeal cardiopulmonary resuscitation patients: analysis of the extracorporeal life support organization registry. *J Heart Lung Transpl off Publ Int Soc Heart Transpl*. 2023;42(4):503–11.
- Kashiura M, Yasuda H, Kishihara Y, et al. Association between short-term neurological outcomes and extreme hyperoxia in patients with out-of-hospital cardiac arrest who underwent extracorporeal cardiopulmonary resuscitation: a retrospective observational study from a multicenter registry. *BMC Cardiovasc Disord*. 2022;22(1):163.
- Tonna JE, Selzman CH, Bartos JA et al. The association of modifiable mechanical ventilation settings, blood gas changes and survival on extracorporeal membrane oxygenation for cardiac arrest. *Resuscitation* 2022;S0300-9572(22)00083 – 1.
- Moussa MD, Beyls C, Lamer A, et al. Early hyperoxia and 28-day mortality in patients on venoarterial ECMO support for refractory cardiogenic shock: a bicenter retrospective propensity score-weighted analysis. *Crit Care Lond Engl*. 2022;26(1):257.
- Celińska-Spodar M, Załęska-Kocięcka M, Banaś S, ARTERIAL HYPEROXIA AND MORTALITY IN PATIENTS UNDERGOING VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION, et al. *Shock Augusta Ga*. 2023;59(1):20–7.
- Lorusso R, Shekar K, MacLaren G et al. ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients. *ASAIO J Am Soc Artif Intern Organs* 1992 2021;67(8):827–44.
- Winiszewski H, Guinot P-G, Schmidt M, et al. Optimizing PO2 during peripheral veno-arterial ECMO: a narrative review. *Crit Care Lond Engl*. 2022;26(1):226.
- Premraj L, Brown A, Fraser JF, Pellegrino V, Pilcher D, Burrell A. Oxygenation during venoarterial extracorporeal membrane oxygenation: physiology, current evidence, and a pragmatic Approach to Oxygen Titration. *Crit Care Med*; 2023.
- Distelmaier K, Roth C, Schrutka L, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. *Br J Anaesth*. 2016;117(1):52–8.
- Ellouze O, Lamirel J, Perrot J, et al. Extubation of patients undergoing extracorporeal life support. A retrospective study. *Perfusion*. 2019;34(1):50–7.
- Lamhaut L, Hutin A, Puymirat E, et al. A pre-hospital extracorporeal Cardio Pulmonary Resuscitation (eCPR) strategy for treatment of refractory out hospital cardiac arrest: an observational study and propensity analysis. *Resuscitation*. 2017;117:109–17.
- Andrei S, Nguyen M, Berthoud V, et al. Determinants of arterial pressure of Oxygen and Carbon Dioxide in patients supported by veno-arterial ECMO. *J Clin Med*. 2022;11(17):5228.
- Justus A, Burrell A, Anstey C, Cormell G, Brodie D, Shekar K. The Association of Oxygenation, Carbon Dioxide removal, and Mechanical Ventilation practices on Survival during Venoarterial extracorporeal membrane oxygenation. *Front Med*. 2021;8:756280.
- Premraj L, Brown A, Burrell A, Fraser JF, Pilcher D. Hyperoxia during venoarterial ECMO: culprit or co-variate? A comment from the BLENDER investigators. *Crit Care Lond Engl*. 2022;26(1):345.
- Hong S, Jang JH, Yang JH, Cho YH, Ahn J, Ryu J-A. Optimal arterial blood gas tensions for the prognosis of favorable neurological outcomes in survivors after extracorporeal cardiopulmonary resuscitation. *J Clin Med*. 2022;11(14):4211.
- Falk L, Sallissalmi M, Lindholm JA, et al. Differential hypoxemia during venoarterial extracorporeal membrane oxygenation. *Perfusion*. 2019;34(1suppl):22–9.

25. Mourad M, Eliet J, Zeroual N, et al. Pulse pressure and end-tidal carbon dioxide for monitoring low native cardiac output during veno-arterial ECLS: a prospective observational study. *Crit Care Lond Engl.* 2020;24(1):569.
26. Joyce CJ, Anderson C, Shekar K. Hyperoxia on Venoarterial extracorporeal membrane oxygenation: a modifiable risk? *Crit Care Med.* 2022;50(1):e99–100.
27. Li Y, Tao Y, Xu J, et al. Hyperoxia provokes Time- and dose-dependent gut Injury and Endotoxemia and alters gut microbiome and transcriptome in mice. *Front Med.* 2021;8:732039.
28. Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. *Am J Respir Crit Care Med.* 2015;191(8):894–901.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.